| Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Greenberg Norman Michael | Chief Scientific Officer | Jun 01 | Option Exercise | 4.56 | 15,000 | 68,400 | 15,000 | Jun 03 05:03 PM | | Greenberg Norman Michael | Chief Scientific Officer | Jun 01 | Sale | 18.38 | 15,000 | 275,760 | 0 | Jun 03 05:03 PM | | Robinson William Hewitt | Director | May 28 | Sale | 20.01 | 600 | 12,003 | 429,861 | May 29 06:50 PM | | Serafini Tito | Chief Strategy Officer | May 27 | Sale | 20.00 | 100 | 2,000 | 456,620 | May 29 06:48 PM | | Robinson William Hewitt | Director | May 26 | Sale | 20.00 | 387 | 7,740 | 430,461 | May 27 05:58 PM | | Serafini Tito | Chief Strategy Officer | May 26 | Sale | 20.00 | 200 | 4,000 | 456,720 | May 27 05:57 PM | | Serafini Tito | Chief Strategy Officer | May 18 | Sale | 20.00 | 1,700 | 34,004 | 456,920 | May 19 05:39 PM | | Robinson William Hewitt | Director | May 18 | Sale | 20.00 | 1,600 | 32,003 | 430,848 | May 19 05:41 PM | | Robinson William Hewitt | Director | May 15 | Sale | 20.00 | 2,100 | 42,000 | 432,448 | May 19 05:41 PM | | Serafini Tito | Chief Strategy Officer | May 15 | Sale | 20.00 | 2,200 | 44,000 | 458,620 | May 19 05:39 PM | | Robinson William Hewitt | Director | May 13 | Sale | 16.82 | 5,000 | 84,105 | 434,548 | May 15 05:45 PM | | Serafini Tito | Chief Strategy Officer | May 11 | Sale | 18.00 | 10,000 | 180,025 | 460,820 | May 13 07:35 PM | | Greenberg Norman Michael | Chief Scientific Officer | May 07 | Option Exercise | 4.56 | 5,000 | 22,800 | 5,000 | May 08 05:28 PM | | Greenberg Norman Michael | Chief Scientific Officer | May 07 | Sale | 18.00 | 5,000 | 90,000 | 0 | May 08 05:28 PM | | Greenberg Norman Michael | Chief Scientific Officer | May 01 | Option Exercise | 4.56 | 10,000 | 45,600 | 10,000 | May 04 05:57 PM | | Greenberg Norman Michael | Chief Scientific Officer | May 01 | Sale | 15.03 | 10,000 | 150,276 | 0 | May 04 05:57 PM | | Serafini Tito | Chief Strategy Officer | Apr 16 | Sale | 16.28 | 10,000 | 162,761 | 470,820 | Apr 20 05:32 PM | | Robinson William Hewitt | Director | Apr 16 | Sale | 16.25 | 5,000 | 81,271 | 439,548 | Apr 20 05:30 PM | | Greenberg Norman Michael | Chief Scientific Officer | Apr 14 | Option Exercise | 4.56 | 5,000 | 22,800 | 5,000 | Apr 16 06:28 PM | | Greenberg Norman Michael | Chief Scientific Officer | Apr 14 | Sale | 18.00 | 5,000 | 90,000 | 0 | Apr 16 06:28 PM | | Greenberg Norman Michael | Chief Scientific Officer | Apr 08 | Option Exercise | 4.56 | 8,000 | 36,480 | 8,000 | Apr 10 05:17 PM | | Greenberg Norman Michael | Chief Scientific Officer | Apr 08 | Sale | 15.01 | 8,000 | 120,101 | 0 | Apr 10 05:17 PM | | Greenberg Norman Michael | Chief Scientific Officer | Apr 01 | Option Exercise | 4.56 | 2,000 | 9,120 | 2,000 | Apr 02 06:18 PM | | Greenberg Norman Michael | Chief Scientific Officer | Apr 01 | Sale | 15.21 | 2,000 | 30,422 | 0 | Apr 02 06:18 PM | | Orwin John A | President & CEO | Mar 17 | Buy | 12.79 | 6,000 | 76,740 | 6,000 | Mar 19 06:52 PM | | Greenberg Norman Michael | Chief Scientific Officer | Mar 02 | Option Exercise | 4.56 | 15,000 | 68,400 | 15,000 | Mar 04 06:18 PM | | Greenberg Norman Michael | Chief Scientific Officer | Mar 02 | Sale | 24.07 | 15,000 | 360,984 | 0 | Mar 04 06:18 PM | | Cavet Guy | Chief Technical Officer | Feb 25 | Option Exercise | 4.56 | 2,100 | 9,576 | 94,858 | Feb 26 06:24 PM | | Cavet Guy | Chief Technical Officer | Feb 25 | Sale | 20.64 | 7,100 | 146,538 | 87,758 | Feb 26 06:24 PM | | Greenberg Norman Michael | Chief Scientific Officer | Feb 03 | Option Exercise | 4.56 | 15,000 | 68,400 | 15,000 | Feb 04 06:00 PM | | Greenberg Norman Michael | Chief Scientific Officer | Feb 03 | Sale | 19.65 | 15,000 | 294,768 | 0 | Feb 04 06:00 PM | | Cavet Guy | Chief Technical Officer | Jan 27 | Sale | 20.00 | 10,000 | 200,000 | 92,758 | Jan 29 04:05 PM | | Greenberg Norman Michael | Chief Scientific Officer | Jan 24 | Option Exercise | 4.56 | 5,000 | 22,800 | 5,000 | Jan 27 04:10 PM | | Greenberg Norman Michael | Chief Scientific Officer | Jan 24 | Sale | 18.47 | 5,000 | 92,346 | 0 | Jan 27 04:10 PM | | Greenberg Norman Michael | Chief Scientific Officer | Jan 17 | Option Exercise | 4.56 | 10,000 | 45,600 | 10,000 | Jan 22 04:15 PM | | Cavet Guy | Chief Technical Officer | Jan 17 | Option Exercise | 5.16 | 1,919 | 9,902 | 109,677 | Jan 22 04:16 PM | | Cavet Guy | Chief Technical Officer | Jan 17 | Sale | 14.90 | 6,919 | 103,065 | 102,758 | Jan 22 04:16 PM | | Greenberg Norman Michael | Chief Scientific Officer | Jan 17 | Sale | 14.90 | 10,000 | 148,992 | 0 | Jan 22 04:15 PM |
|
